Find Clinical Trial
Clinical long-term effects of Valdoxan® (25 or 50 mg) in depressed patients. Clinical, national, interventional, phase IV, multicentre, open study. Valdoxan® D-EXTENSION Study
← Back
| Study Phase |
Phase 4 |
| Therapeutic Area |
Neuropsychiatric Diseases |
| Indication | Major Depressive Disorder |
| Sponsor | EUTHERAPIE / Les Laboratoires Servier |
| Active substance/ Medical device |
AGOMELATINE, |
| Active Substance Code | S020098 |
| Protocol Code | DM4-20098-112 |
| EudraCT Code | 2009-010112-15 |
Documents and links
| Results summary | READ MORE  |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
